October 2024 – Novogene, a global leader in genomic services and solutions, is proud to announce the launch of Falcon III, its latest next-generation sequencing (NGS) automation platform, in its Munich lab in Germany. Designed to streamline multiple NGS workflow processes, it marks a significant advancement in sequencing efficiency and flexibility.

Falcon III offers unparalleled performance, building upon the success of its predecessor, Falcon II. Compact and efficient, the platform occupies just 5m² while delivering a 25% increase in production capacity over Falcon II. The new system continues to enhance Novogene’s commitment to providing industry-leading, high-quality NGS services to its customers across Europe.

• Intelligence and Automation

Falcon III integrates eight precision instruments to automate the entire process of both DNA and RNA sequencing. This includes everything from library construction to library pooling, making the platform a highly intelligent solution for advanced NGS applications.

• Enhanced Efficiency

With innovative technology that eliminates the need for sample collection, Falcon III allows for flexible ordering and customizable workflows. Capable of processing over 400 samples per day, the platform doubles production efficiency compared to manual processing methods.

• Superior Quality

Falcon III consistently demonstrates contamination-free operations and precise sample tracking, ensuring the highest quality outcomes for DNA and RNA-seq NGS projects.

• Flexibility and Reliability

Featuring parallel production lines, Falcon III allows for rapid recovery in the event of a fault, with one line always on standby. The system is modular and miniaturized, all within a small 5m² footprint, offering flexibility for on-demand starts and real-time order insertion.

Innovation and Development

Falcon III represents the culmination of extensive R&D by Novogene’s automation team, which includes specialists in software development, mechanical engineering and precision control. By addressing key customer needs and leveraging advanced scheduling algorithms and process optimization, the team has created a platform that delivers cutting-edge automation. Novogene retains full intellectual property rights for the central control software, which serves as the backbone of the Falcon III platform.

Global Deployment

The Falcon series is already operational in Novogene laboratories in the UK, the US, and China. These systems are significantly enhancing processing times, quality and operational efficiency. Novogene plans to roll out the Falcon III platform across its global facilities, further increasing the capacity and scale of its sequencing services while providing consistent, high-quality support to customers worldwide.

Commitment to Excellence

At the core of Novogene’s mission is a commitment to delivering the highest-quality genomic solutions while continuously improving the customer experience through innovation. The Falcon series (Falcon, Falcon II, and now Falcon III) embodies this vision, offering unparalleled advancements in digitization, automation and service delivery. As Novogene continues to evolve its intelligent systems, customers can expect even greater efficiency, stability and quality in their NGS projects.

About Novogene

Novogene is a world leader in genomic services, specializing in next-generation sequencing and bioinformatics. With one of the largest sequencing capacities globally, Novogene leverages its extensive expertise to deliver superior data quality and service. The company’s global team of nearly 2,000 professionals has contributed to over 26,520 SCI publications, including prominent journals such as Cell, Nature and Science. Novogene’s 76 NGS-related patents and cutting-edge technology make it a trusted partner in the rapidly advancing field of genomics.